Orforglipron
Lilly's GLP-1 pill, FDA approved in 2026 as Foundayo. A small molecule, not a peptide, and vendor listings are not the approved tablet.
Also listed as Orforglipron Tablets, LY3502970, Orforglipron Tablet.
Peptide Compare tracked 1 vendor selling Orforglipron on 21 Sep 2026. The cheapest in-stock 10 mg vial is $9.00 per mg at Umbrella Labs. Prices are scraped from vendor sites; trust scores come from Finnrick blind tests.
Some outbound links may earn us a commission. Vendors cannot pay to improve rankings.
Best value right now · all sizes
UL
Umbrella Labs
IN STOCKUNTESTED
Per mg
Vial price10 mg · verified Sep 21
Compare 1 vendor
Across all sizes, verified in-stock listings run $89.99 to $89.99 from 1 vendor.
VendorSizeStock
Orforglipron prices verified Sep 21, 2026
$9.00/mgUmbrella Labs · $89.99
Buy best priceSee how Orforglipron moved against the rest of the catalogue in the Peptide Price Index: median price per mg now versus 30 and 90 days ago, every tracked peptide, with a CSV.
Orforglipron price by vial size
| Vial size | Lowest per mg | Vial price | Vendor |
|---|---|---|---|
| 10 mg | $9.00 | $89.99 | Umbrella Labs1 vendor carries it |
Verified 21 Sep 2026. Lowest figures are in-stock listings checked within the last week, with any coupon applied; a size with none says so.
Price movement · 30 days
0%median per mg, all sizes
Cheapest ever recorded: $9.00/mg on Aug 7. Today matches it.Quick Summary
An oral, small-molecule GLP-1 receptor agonist from Eli Lilly, approved by the FDA in 2026 as Foundayo for weight management. It is a non-peptide pill, so a research vendor selling this name is selling a small molecule rather than a peptide, and never the approved tablet. Available from 1 vendor, starting at $89.99.
Research: ATTAIN-1 (Wharton et al, NEJM 2025;393(18):1796-1806, PMID 40960239) randomised 3,127 adults with obesity and no diabetes for 72 weeks. Mean weight change on the treatment-regimen estimand was -7.5% at 6 mg, -8.4% at 12 mg and -11.2% at 36 mg. Placebo was -2.1%. In the 36 mg group, 54.6% lost 10% or more and 18.4% lost 20% or more. On placebo those shares were 12.9% and 2.8%.
Side effects: From the Foundayo US prescribing information (revised July 2026), reported in 5% or more of patients: nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, reflux, flatulence and hair loss, a boxed warning for thyroid C-cell tumors, as for other GLP-1 receptor agonists, in ATTAIN-1, adverse events led 5.3% to 10.3% of patients on orforglipron to stop treatment, against 2.7% on placebo
FDA-approvedFoundayo (Eli Lilly), NDA 220934, initial US approval 2026, for long-term weight management with diet and activity in adults with obesity, or with overweight and a weight-related condition. Vendor listings on this page are research chemicals, not Foundayo.
- 1 of 1 vendor currently have it in stock
- Most common vial size: 10mg
- Category: Weight Loss (GLP-1) — GLP-1 receptor agonists for weight management
Get Orforglipron price alerts
Join the list — price-drop alerts for this peptide are in the works and you'll be first on them.